Story

Cintas Stock Surges on Strong Earnings and Upbeat 2027 Forecast

ENTHMSVIIDZHZH-TWJAKOHI
Jul 15, 20261 min read
Cintas Stock Surges on Strong Earnings and Upbeat 2027 Forecast

Summary

Cintas shares jumped after the company reported fiscal fourth-quarter earnings and revenue that topped analyst estimates, and issued an optimistic financial outlook for fiscal 2027.

Text size
Background

Shares of Cintas (CTAS) surged more than 5% in morning trading Wednesday after the business services company announced fiscal fourth-quarter results that surpassed Wall Street expectations and provided a strong forecast for the upcoming year.

Quarterly Performance Exceeds Expectations

Cintas reported financial results for its fiscal fourth quarter of 2026 before the market opened, revealing solid top- and bottom-line growth. The performance extended the company's streak of consecutive quarterly earnings beats.

  • Earnings Per Share (EPS): $1.29, beating the consensus estimate of $1.24.
  • Revenue: $2.91 billion, ahead of the expected $2.87 billion and representing an 8.9% increase year-over-year.
  • Gross Margin: Reached 51.0%, matching the company's all-time high and expanding by 130 basis points from the prior-year period. This signals strong pricing power and operating efficiency.

Optimistic Outlook Drives Investor Confidence

Beyond the strong quarter, Cintas issued an upbeat financial outlook for fiscal 2027, giving investors confidence that its growth momentum will continue. Management's revenue guidance came in slightly above what analysts had modeled.

Sample IUX Markets – In-articleAd

For fiscal 2027, the company projects:

  • Revenue: Between $12.10 billion and $12.25 billion.
  • Adjusted EPS: In the range of $5.36 to $5.50.

Market Reaction

The strong earnings and robust guidance provided a catalyst for the stock, which had been trading in a consolidated range since March. The rally to a session high of $196.69 was driven by company-specific fundamentals, significantly outpacing modest gains in the broader U.S. equity market. The positive results overshadowed any potential investor uncertainty surrounding the company's pending acquisition of UniFirst, which remains under regulatory review.

Read next

More on Stocks
Shenzhen-Listed Jingxin Pharmaceutical Refiles for Hong Kong IPO

Stocks

Shenzhen-Listed Jingxin Pharmaceutical Refiles for Hong Kong IPO

Sep 20, 2026

Zhejiang Jingxin Pharmaceutical Co., Ltd. (002020.SZ) has resubmitted its application for a main board listing on the Hong Kong Stock Exchange, aiming to secure a dual listing to access international capital. The company specializes in drugs for central nervous system and cardiovascular diseases.

Back to latest news

LATEST